Neoadjuvant immunotherapy improves outcomes of patients with high-risk melanoma

Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery.

Leave A Comment

Your email address will not be published. Required fields are marked *